Rifampicin/isoniazid/pyrazinamide
From Wikipedia, the free encyclopedia
| Combination of | |
|---|---|
| Rifampicin | Rifamycin antibiotic |
| Isoniazid | First-line anti-tuberculosis medication |
| Pyrazinamide | Anti-tuberculosis medication |
| Clinical data | |
| Trade names | Rifater, Trifazid |
| AHFS/Drugs.com | FDA Professional Drug Information |
| Pregnancy category |
|
| Routes of administration |
Oral |
| Legal status | |
| Legal status |
|
| Identifiers | |
| ATC code | J04AM05 (WHO) |
| PubChem | CID 6474062 |
| (verify) | |
Rifampicin/isoniazid/pyrazinamide (trade name Rifater) is a fixed dose combination tablet manufactured by Aventis used in the treatment of tuberculosis. Each tablet contains 120 mg rifampicin, 50 mg isoniazid and 300 mg pyrazinamide. It is used in initial treatment of tuberculosis, typically for the first two months.[1][2]
Rifater is contraindicated in children with a body weight of under 40 kg.[2]
The purpose of the fixed dose combination is to make it easier for patients to take their medication; but also to ensure that if patients forget to take one or two of their drugs, they do not then develop resistance to the remaining drugs.
See also[edit]
References[edit]
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |
